ImmuPharma advances P140 partnering talks as patent progress and new study data strengthen programme

ImmuPharma PLC (AIM:IMM, FRA:25I), the AIM-listed specialist drug discovery and development company, is progressing discussions with a number of potential partners for its P140 autoimmune technology platform, including under signed confidentiality agreements, as it targets a value-enhancing licensing deal in 2026. The company's management team attended the Bio-Europe Spring healthcare conference in Lisbon this week, where a number of meetings were held in relation to P140, which ImmuPharma describes as a core value driver for the business.